SCFSkp2 Inhibitors Targeting p27-Binding Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those targeting the ubiquitin proteasome system, face limitations such as resistance development and side effects like peripheral neuropathy, and lack specific inhibitors for the SCF-Skp2 E3 ligase, which plays a crucial role in tumor suppressor degradation.
Innovation Solution
Development of small molecule inhibitors that selectively target the SCF-Skp2 activity by binding to the p27-binding interface of the Skp2-Cks1 complex, using a structure-based drug discovery approach combining virtual ligand screening and in vitro assays to identify compounds that inhibit Skp2-mediated p27 degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proteasome inhibitors like Bortezomib are used to treat cancer, then tumor suppressor degradation is inhibited, but peripheral neuropathy and resistance develop
Solution Approach 1:
The patent extracts the harmful off-target effects by specifically targeting the SCF-Skp2 E3 ligase complex, separating the therapeutic action from the harmful peripheral neuropathy side effects associated with non-specific proteasome inhibition. This selective targeting approach maintains cancer treatment efficacy while eliminating the harmful factor.
Solution Approach 2:
The invention applies local quality by designing inhibitors that specifically target the SCF-Skp2 complex at the p27-binding interface, creating localized therapeutic activity only where needed in cancer cells, rather than systemically inhibiting the entire proteasome pathway and causing widespread side effects.
2Reliability
If proteasome inhibitors are used to treat cancer, then tumor suppressor degradation is inhibited, but resistance develops
Solution Approach 1:
The patent extracts the mechanism of resistance by targeting SCF-Skp2 upstream of the proteasome, separating the therapeutic action from the resistance development pathway. This upstream targeting prevents the adaptive responses that lead to proteasome inhibitor resistance.
Solution Approach 2:
The invention applies preliminary action by inhibiting SCF-Skp2-mediated p27 degradation before the proteasome can be activated, preventing the cancer cells from developing resistance mechanisms that would otherwise arise during proteasome inhibition treatment.
3Quantity of substance
If SCF-Skp2 E3 ligase is inhibited, then p27 protein levels increase, but specific inhibitors are needed to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the SCF-Skp2 complex at the p27-binding interface, creating localized therapeutic activity only where needed in cancer cells, rather than systemically inhibiting the entire proteasome pathway and causing widespread side effects.
Solution Approach 2:
The invention uses an intermediary approach by targeting the Skp2-Cks1 complex interface as a mediating structure between the inhibitor and the downstream effects. This intermediary target allows specific modulation of p27 stability without directly affecting the proteasome or other UPS components.
4Manufacturing precision
If structure-based drug discovery is used to identify SCF-Skp2 inhibitors, then compound specificity is improved, but development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by performing virtual ligand screening and structure-based design before initiating experimental validation, identifying promising compounds in advance and reducing the time required for iterative optimization and testing phases.
Solution Approach 2:
The invention uses copying by employing virtual ligand screening to create computational models of SCF-Skp2 inhibitors before synthesizing actual compounds. This virtual copying allows rapid identification and optimization of candidate structures without immediate physical synthesis, reducing overall development time.
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.